Význam analýzy nestinu u mnohočetného myelomu

English version

Authors: H. Šváchová ^1,2; L. Kovářová ^1,4; J. Štossová ¹; A. Potáčová ¹; L. Pour ^1,3; R. Hájek ^1,3,4
Authors‘ workplace: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ¹; Department of Experimental Biology, Faculty of Science, Masaryk University ²; Department of Internal Medicine – Hematooncology, University Hospital Brno, Czech Republic ³; Laboratory of Experimental Hematology and Cell Immunotherapy, Department of Clinical Haematology, University Hospital Brno ⁴
Published in: Klin Onkol 2011; 24(Supplementum 1): 53-57

Overview

Nestin, marker multipotentních prekurzorových buněk, představuje významnou dynamickou strukturu, jejíž polymerizace/depolymerizace ovlivňuje intracelulární signalizaci a podílí se na řadě klíčových buněčných procesů, jako je proliferace, migrace a přežívání buněk. Předpokládá se, že nestin hraje centrální roli v procesu karcinogeneze. Nestin je považován za možný diagnostický a prediktivní indikátor malignity solidních nádorů a potenciální marker nádorových kmenových buněk. Překvapivě byl identifikován i ve zralých CD138+38+ plazmatických buňkách (PC) mnohočetného myelomu (MM). Exprese markeru kmenových/progenitorových buněk v maligních PC, které jsou považovány za terminálně diferencované, indikuje, že nestin by mohl hrát významnou roli v patologii MM.

Klíčová slova:
nestin – plazmatické buňky – mnohočetný myelom – myelomové kmenové buňky – myelom-iniciující buňky – flowcytometrie

Tato práce byla podpořena výzkumnými projekty MŠMT ČR:
LC06027, MSM0021622434; granty IGA MZ ČR: NS10406, NS10408, NT11154 a granty GAČR GAP304/10/1395.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.

Sources

1. Billadeau D, Ahmann G, Greipp P et al. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178(3): 1023–1031.

2. Hájek R, Maisnar V, Krejčí M. Thalidomid. Klin Farmakol Farm 2005; 19(1): 43–46.

3. Hájek R, Holánek M. Lenalidomid v léčbě mnohočetného myelomu. Farmakoterapie 2009; 2(5): 159–163.

4. Berenson JR, Yang HH, Sadler K et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24(6): 937–944.

5. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351(18): 1860–1873.

6. Kyle RA. New strategies for MGUS and smoldering multiple myeloma. Clin Adv Hematol Oncol 2004; 2(8): 507–509.

7. Matsui W, Huff CA, Wang Q et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103(6): 2332–2336.

8. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94(10): 3576–3582.

9. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 2005; 11(21): 7599–7606.

10. Svachova H, Pour L, Sana J et al. Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients. Leuk Res 2011. Epub ahead of print.

11. Spisek R, Kukreja A, Chen LC et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204(4): 831–840.

12. Jungbluth AA, Ely S, DiLiberto M et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005; 106(1): 167–174.

13. Zhu L, Somlo G, Zhou B et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005; 4(5): 787–798.

14. Nečasová J, Kadlecová J, Spěšná R et al. Význam sledování exprese nádorových testikulárních antigenů u mnohočetného myelomu.Klin Onkol 2008; 21 (Suppl 4): 223–225.

15. Hockfield S, McKay RD. Identification of major cell classes in the developing mammalian nervous system. J Neurosci 1985; 5(12): 3310–3328.

16. Sjöberg G, Jiang WQ, Ringertz NR et al. Colocalization of nestin and vimentin/desmin in skeletal muscle cells demonstrated by three-dimensional fluorescence digital imaging microscopy. Exp Cell Res 1994; 214(2): 447–458.

17. Walcott JC, Provis JM. Müller cells express the neuronal progenitor cell marker nestin in both differentiated and undifferentiated human foetal retina. Clin Experiment Ophthalmol 2003; 31(3): 246–249.

18. Sun XY, An J. Expression of nestin, an intermediate filament protein, in human fetal hepatic stem cells. Di Yi Jun Yi Da Xue Xue Bao 2004; 24(2): 207–209.

19. Vanderwinden JM, Gillard K, de Laet MH et al. Distribution of the intermediate filament nestin in the muscularis propria of the human gastrointestinal tract. Cell Tissue Res 2002; 309(2): 261–268.

20. Mayer EJ, Hughes EH, Carter DA et al. Nestin positive cells in adult human retina and in epiretinal membranes. Br J Ophthalmol 2003; 87(9): 1154–1158.

21. Lothian C, Prakash N, Lendahl U et al. Identification of both general and region-specific embryonic CNS enhancer elements in the nestin promoter. Exp Cell Res 1999; 248(2): 509–519.

22. Lobo MV, Arenas MI, Alonso FJ et al. Nestin, a neuroectodermal stem cell marker molecule, is expressed in Leydig cells of the human testis and in some specific cell types from human testicular tumours. Cell Tissue Res 2004; 316(3): 369–376.

23. Marvin MJ, Dahlstrand J, Lendahl U et al. A rod end deletion in the intermediate filament protein nestin alters its subcellular localization in neuroepithelial cells of transgenic mice. J Cell Sci 1998; 111 (Pt 14): 1951–1961.

24. Michalczyk K, Ziman M. Nestin structure and predicted function in cellular cytoskeletal organization. Histol Histopathol 2005; 20(2): 665–671.

25. Coulombe PA, Wong P. Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. Nat Cell Biol 2004; 6(8): 699–706.

26. Steinert PM, Chou YH, Prahlad V et al. A high molecular weight intermediate filament-associated protein in BHK-21 cells is nestin, a type VI intermediate filament protein. Limited co-assembly in vitro to form heteropolymers with type III vimentin and type IV alpha-internexin. J Biol Chem 1999; 274(14): 9881–9890.

27. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell 1990; 60(4): 585–595.

28. Kachinsky AM, Dominov JA, Miller JB. Intermediate filaments in cardiac myogenesis: nestin in the developing mouse heart. J Histochem Cytochem 1995; 43(8): 843–847.

29. Vaittinen S, Lukka R, Sahlgren C et al. The expression of intermediate filament protein nestin as related to vimentin and desmin in regenerating skeletal muscle. J Neuropathol Exp Neurol 2001; 60(6): 588–597.

30. Chou YH, Khuon S, Herrmann H et al. Nestin promotes the phosphorylation-dependent disassembly of vimentin intermediate filaments during mitosis. Mol Biol Cell 2003; 14(4): 1468–1478.

31. Sahlgren CM, Mikhailov A, Hellman J et al. Mitotic reorganization of the intermediate filament protein nestin involves phosphorylation by cdc2 kinase. J Biol Chem 2001; 276(19): 16456–16463.

32. Sahlgren CM, Pallari HM, He T et al. A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. EMBO J 2006; 25(20): 4808–4819.

33. Wiese C, Rolletschek A, Kania G et al. Nestin expression – a property of multi-lineage progenitor cells? Cell Mol Life Sci 2004; 61(19–20): 2510–2522.

34. About I, Laurent-Maquin D, Lendahl U et al. Nestin expression in embryonic and adult human teeth under normal and pathological conditions. Am J Pathol 2000; 157(1): 287–295.

35. Ha Y, Kim T, Yoon DH et al. Reinduced expression of developmental proteins (nestin, small heat shock protein) in and around cerebral arteriovenous malformations. Clin Neuropathol 2003; 22(5): 252–261.

36. Klein T, Ling Z, Heimberg H et al. Nestin is expressed in vascular endothelial cells in the adult human pancreas. J Histochem Cytochem 2003; 51(6): 697–706.

37. Gu H, Wang S, Messam CA et al. Distribution of nestin immunoreactivity in the normal adult human forebrain. Brain Res 2002; 943(2): 174–180.

38. Qiang L, Yang Y, Ma YJ et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 2009; 279(1): 13–21.

39. Veselska R, Kuglik P, Cejpek P et al. Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer 2006; 6: 32.

40. Krupkova O Jr, Loja T, Zambo I et al. Nestin expression in human tumors and tumor cell lines. Neoplasma 2010; 57(4): 291–298.

41. Yamada H, Takano T, Ito Y et al. Expression of nestin mRNA is a differentiation marker in thyroid tumors. Cancer Lett 2009; 280(1): 61–64.

42. Liu S, Otsuyama K, Ma Z e al. Induction of multilineage markers in human myeloma cells and their down-regulation by interleukin 6. Int J Hematol 2007; 85(1): 49–58.

43. Ignatova TN, Kukekov VG, Laywell ED et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39(3): 193–206.

44. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65(20): 9328–9337.

45. Kovářová L, Buršová I, Suská R et al. Rozlišení nádorových klonálních a fyziologických polyklonálch plazmatických buněk pomocí flocytometrie. Klin Onkol 2008; 21 (Suppl 1): 254–257.

46. Kovarova L, Buresova I, Buchler T et al. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Neoplasma 2009; 56(6): 526–532.

47. Balik V, Mirossay P, Bohus P et al. Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. Cell Mol Neurobiol 2009; 29(6–7): 845–858.

48. van Stijn A, Kok A, van der Pol MA et al. Multiparameter flow cytometric quantification of apoptosis-related protein expression. Leukemia 2003; 17(4): 787–788.

49. Means AL, Meszoely IM, Suzuki K et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 2005; 132(16): 3767–3776.

50. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? Cell 2001; 105(7): 829–841.

51. Kleeberger W, Bova GS, Nielsen ME et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 2007; 67(19): 9199–1206.